Compare Morgan Stanley (MS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Organon & Co. Common Stock — how do they compare? Morgan Stanley trades at $181.4 (market cap $293.13B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Morgan Stanley is far larger — about 81× Organon & Co. Common Stock's market cap, and Morgan Stanley pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 90 Days and Organon & Co. Common Stock for 0 Days on average.
| MS | OGN | |
|---|---|---|
Market Cap | $293.13B | $3.62B |
Volume | 8,184,975 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $228.42 | $13.81 |
52-Week Low | $154.37 | $5.70 |
Typical Hold Time | 90 Days | 0 Days |
Enterprise Value | $658.86B | $11.04B |
Dividend Yield | 2.46% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $186.66, down 1.77% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $50.2B in 2022 to $66.0B in 2025, and a net income margin of 27.59%. Analyst consensus is bullish with a $225.50 price target, supported by growth in wealth management and AI financing.
The outlook remains positive given earnings momentum and strategic initiatives, but risks include volatile cash flows, high debt levels, and market sensitivity. Upside potential exists if the company capitalizes on capital markets recovery and AI demand, though investors should monitor leverage and macroeconomic headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
